Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Serum vitamin D decreases during chemotherapy: an Australian prospective cohort study.

Isenring EA, Teleni L, Woodman RJ, Kimlin MG, Walpole E, Karapetis CS, Shawgi S, Kichenadasse G, Marshall S, Koczwara B.

Asia Pac J Clin Nutr. 2018;27(5):962-967. doi: 10.6133/apjcn.042018.01.

2.

Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.

Tran LNK, Kichenadasse G, Sykes PJ.

Curr Cancer Drug Targets. 2018 Jul 23. doi: 10.2174/1568009618666180724111604. [Epub ahead of print]

PMID:
30039761
3.

Competing Risks in Older Patients With Cancer: A Systematic Review of Geriatric Oncology Trials.

Burdett N, Vincent AD, O'Callaghan M, Kichenadasse G.

J Natl Cancer Inst. 2018 Aug 1;110(8):825-830. doi: 10.1093/jnci/djy111.

PMID:
30011032
4.

Prostate cancer mortality is high in the elderly and can be reduced by selective individualized curative treatment.

Moretti K, Vatandoust S, Kichenadasse G, O'Callaghan ME, Vincent AD, Kopsaftis T, Walsh S, Borg M, Karapetis C.

World J Urol. 2018 Nov;36(11):1799-1800. doi: 10.1007/s00345-018-2312-9. Epub 2018 May 10. No abstract available.

PMID:
29748854
5.

Online information and support needs of women with advanced breast cancer: a qualitative analysis.

Kemp E, Koczwara B, Butow P, Turner J, Girgis A, Schofield P, Hulbert-Williams N, Levesque J, Spence D, Vatandoust S, Kichenadasse G, Roy A, Sukumaran S, Karapetis CS, Richards C, Fitzgerald M, Beatty L.

Support Care Cancer. 2018 Oct;26(10):3489-3496. doi: 10.1007/s00520-018-4206-1. Epub 2018 Apr 24.

PMID:
29693203
6.

Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry.

Vatandoust S, Kichenadasse G, O'Callaghan M, Vincent AD, Kopsaftis T, Walsh S, Borg M, Karapetis CS, Moretti K.

BJU Int. 2018 May;121 Suppl 3:48-54. doi: 10.1111/bju.14228.

7.

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.

Mangoni AA, Kichenadasse G, Rowland A, Sorich MJ.

Ther Adv Med Oncol. 2018 Feb 5;10:1758834018755090. doi: 10.1177/1758834018755090. eCollection 2018.

8.

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

Hopkins AM, Rowland A, Kichenadasse G, Wiese MD, Gurney H, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2017 Sep 26;117(7):913-920. doi: 10.1038/bjc.2017.274. Epub 2017 Aug 24. Review.

9.

The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer.

Tran LNK, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, Michael MZ, Lower KM, Sykes PJ.

Mol Cancer Ther. 2017 Dec;16(12):2689-2700. doi: 10.1158/1535-7163.MCT-17-0074. Epub 2017 Aug 11.

PMID:
28802253
10.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

11.

Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer.

Hsieh AH, Tahkar H, Koczwara B, Kichenadasse G, Beckmann K, Karapetis C, Sukumaran S.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e64-e70. doi: 10.1111/ajco.12674. Epub 2017 Mar 8.

PMID:
28276170
12.

Targeted pharmacotherapy after somatic cancer mutation screening.

Polasek TM, Ambler K, Scott HS, Sorich MJ, Kaub PA, Rowland A, Wiese MD, Kichenadasse G.

Version 2. F1000Res. 2016 Jun 30 [revised 2016 Jan 1];5:1551. doi: 10.12688/f1000research.9040.2. eCollection 2016.

13.

Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.

Miners JO, Chau N, Rowland A, Burns K, McKinnon RA, Mackenzie PI, Tucker GT, Knights KM, Kichenadasse G.

Biochem Pharmacol. 2017 Apr 1;129:85-95. doi: 10.1016/j.bcp.2017.01.002. Epub 2017 Jan 6.

PMID:
28065859
14.

The current practice, preparedness and educational preparation of oncology professionals to provide spiritual care.

Kichenadasse G, Sweet L, Harrington A, Ullah S.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e506-e514. doi: 10.1111/ajco.12654. Epub 2016 Dec 22.

PMID:
28004882
15.

Infliximab for ipilimumab-induced colitis: A series of 13 patients.

Hillock NT, Heard S, Kichenadasse G, Hill CL, Andrews J.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e284-e290. doi: 10.1111/ajco.12651. Epub 2016 Dec 16.

PMID:
27981760
16.

Pregnancy screening prior to chemotherapy administration.

Hu L, Kichenadasse G, Martin H, Roy A, Sukumaran S, Vatandoust S, Koczwara B, Karapetis CS.

Intern Med J. 2016 Oct;46(10):1222-1224. doi: 10.1111/imj.13214.

PMID:
27734613
17.

Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.

Shahnam A, Ridha Z, Wiese MD, Kichenadasse G, Sorich MJ.

Pharmacogenomics. 2016 Oct;17(15):1725-1732. Epub 2016 Sep 16.

PMID:
27636246
18.

Safety Study of Salmeterol in Asthma in Adults.

Wilsdon T, Kichenadasse G, Rowland A.

N Engl J Med. 2016 Sep 15;375(11):1096-7. doi: 10.1056/NEJMc1608323. No abstract available.

19.

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.

Rowland A, van Dyk M, Mangoni AA, Miners JO, McKinnon RA, Wiese MD, Rowland A, Kichenadasse G, Gurney H, Sorich MJ.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):31-49. Epub 2016 Sep 1. Review.

PMID:
27561659
20.

A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing.

van Dyk M, Miners JO, Kichenadasse G, McKinnon RA, Rowland A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:17-26. doi: 10.1016/j.jchromb.2016.07.046. Epub 2016 Jul 26.

PMID:
27521531
21.

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

Lawrence N, Martin A, Toner G, Stockler M, Buizen L, Thomson D, Gebski V, Friedlander M, Yeung A, Wong N, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong S, Lewis C, Vasey P, Grimison P.

Ann Oncol. 2016 Dec;27(12):2302-2303. doi: 10.1093/annonc/mdw313. Epub 2016 Aug 8. No abstract available.

PMID:
27502724
22.

Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer.

Hsieh AH, Kichenadasse G, Vatandoust S, Roy A, Sukumaran S, Karapetis CS, Martin H, Chong LC, Koczwara B.

Intern Med J. 2016 Oct;46(10):1153-1159. doi: 10.1111/imj.13169.

PMID:
27389059
23.

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.

Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA.

Br J Cancer. 2016 Jun 14;114(12):1313-7. doi: 10.1038/bjc.2016.147. Epub 2016 May 26.

24.

A Pilot Study of Self-Management-based Nutrition and Physical Activity Intervention in Cancer Survivors.

Miller M, Zrim S, Lawn S, Woodman R, Leggett S, Jones L, Karapetis C, Kichenadasse G, Sukumaran S, Roy AC, Koczwara B.

Nutr Cancer. 2016 Jul;68(5):762-71. doi: 10.1080/01635581.2016.1170169. Epub 2016 May 13.

PMID:
27176450
25.

Prostate cancer in men aged less than 50 years at diagnosis.

Kinnear NJ, Kichenadasse G, Plagakis S, O'Callaghan ME, Kopsaftis T, Walsh S, Foreman D.

World J Urol. 2016 Nov;34(11):1533-1539. Epub 2016 Apr 12.

PMID:
27072535
26.

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, Kichenadasse G, Ackland S, Wheeler H.

J Neurooncol. 2016 May;128(1):163-171. doi: 10.1007/s11060-016-2094-0. Epub 2016 Mar 2.

PMID:
26935578
27.

Acrokeratosis paraneoplastica (Bazex syndrome) associated with metastatic cutaneous squamous cell carcinoma.

Vatandoust S, McKay BP, McLeay W, Miliauskas J, Gordon L, Wesley JA, Kichenadasse G.

Intern Med J. 2016 Jan;46(1):119-20. doi: 10.1111/imj.12955. No abstract available.

PMID:
26813906
28.

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ.

Eur J Cancer. 2016 Mar;55:122-30. doi: 10.1016/j.ejca.2015.11.025. Epub 2016 Jan 23. Review.

PMID:
26812186
29.

Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.

Sorich MJ, Kichenadasse G, Rowland A, Woodman RJ, Mangoni AA.

Int J Cancer. 2016 May 1;138(9):2293-9. doi: 10.1002/ijc.29972. Epub 2016 Jan 6.

30.

Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2015 Dec 1;113(11):1635. doi: 10.1038/bjc.2015.325. Epub 2015 Sep 10. No abstract available.

31.

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Epub 2015 May 19. Review.

32.

Informed decision making about prostate cancer screening.

O'Callaghan ME, Kichenadasse G, Vatandoust S, Moretti K.

Ann Intern Med. 2015 Mar 17;162(6):457. doi: 10.7326/L15-5063. No abstract available.

PMID:
25775324
33.

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.

Ann Oncol. 2015 Jun;26(6):1118-23. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20.

PMID:
25701452
34.

Delayed onset of benign pleural effusion following concurrent chemoradiotherapy for inoperable non-small-cell lung cancer.

Kumar R, Patel G, Kichenadasse G, Sukumaran S, Roy A, Koczwara B, Bowden JJ, Leung J, Woo T, Karapetis CS.

Intern Med J. 2015 Feb;45(2):218-21. doi: 10.1111/imj.12658.

PMID:
25650537
35.

Is self-management feasible and acceptable for addressing nutrition and physical activity needs of cancer survivors?

Lawn S, Zrim S, Leggett S, Miller M, Woodman R, Jones L, Kichenadasse G, Sukumaran S, Karapetis C, Koczwara B.

Health Expect. 2015 Dec;18(6):3358-73. doi: 10.1111/hex.12327. Epub 2014 Dec 28.

36.

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.

Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41. doi: 10.1097/IGC.0000000000000265. Review.

PMID:
25341578
37.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers.

Reed NS, Pautier P, Åvall-Lundqvist E, Choi CH, du Bois A, Friedlander M, Fyles A, Kichenadasse G, Provencher DM, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S30-4. doi: 10.1097/IGC.0000000000000293. Review.

PMID:
25341577
38.

Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.

Padman S, Lee J, Kumar R, Slee M, Hakendorf P, Richards A, Koczwara B, Kichenadasse G, Sukumaran S, Roy A, Vatandoust S, Karapetis CS.

Support Care Cancer. 2015 Mar;23(3):861-9. doi: 10.1007/s00520-014-2423-9. Epub 2014 Sep 16.

PMID:
25223350
39.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12. Review.

PMID:
25115304
40.

Returning to work following curative chemotherapy: a qualitative study of return to work barriers and preferences for intervention.

Knott V, Zrim S, Shanahan EM, Anastassiadis P, Lawn S, Kichenadasse G, Sukumaran S, Karapetis C, Koczwara B.

Support Care Cancer. 2014 Dec;22(12):3263-73. doi: 10.1007/s00520-014-2324-y. Epub 2014 Jul 29.

PMID:
25066834
41.

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.

Hocking CM, Kichenadasse G.

Support Care Cancer. 2014 Apr;22(4):1143-51. doi: 10.1007/s00520-014-2138-y. Epub 2014 Feb 13. Review.

PMID:
24522741
42.

Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

Grimison PS, Stockler MR, Chatfield M, Thomson DB, Gebski V, Friedlander M, Boland AL, Houghton B, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong SS, Lewis CR, Vasey PA, Toner GC; Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Ann Oncol. 2014 Jan;25(1):143-8. doi: 10.1093/annonc/mdt369.

PMID:
24356625
43.

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study.

Blinman P, Gainford C, Donoghoe M, Martyn J, Blomfield P, Grant P, Kichenadasse G, Vaughan M, Brand A, Shannon C, Gebski V, Stockler M, Friedlander M.

J Gynecol Oncol. 2013 Oct;24(4):359-66. doi: 10.3802/jgo.2013.24.4.359. Epub 2013 Oct 2.

44.

Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies.

Patel GS, Jain K, Kumar R, Strickland AH, Pellegrini L, Slavotinek J, Eaton M, McLeay W, Price T, Ly M, Ullah S, Koczwara B, Kichenadasse G, Karapetis CS.

Support Care Cancer. 2014 Jan;22(1):121-8. doi: 10.1007/s00520-013-1941-1. Epub 2013 Sep 5.

PMID:
24005884
45.

Non-vascular drug eluting stents as localized controlled drug delivery platform: preclinical and clinical experience.

Shaikh M, Kichenadasse G, Choudhury NR, Butler R, Garg S.

J Control Release. 2013 Nov 28;172(1):105-117. doi: 10.1016/j.jconrel.2013.08.010. Epub 2013 Aug 17. Review.

PMID:
23958902
46.

Abiraterone in metastatic prostate cancer.

Kichenadasse G, Karapetis C.

N Engl J Med. 2013 Apr 11;368(15):1457. doi: 10.1056/NEJMc1301594. No abstract available.

PMID:
23574134
47.

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.

Olver IN, Grimison P, Chatfield M, Stockler MR, Toner GC, Gebski V, Harrup R, Underhill C, Kichenadasse G, Singhal N, Davis ID, Boland A, McDonald A, Thomson D; Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Support Care Cancer. 2013 Jun;21(6):1561-8. doi: 10.1007/s00520-012-1696-0. Epub 2012 Dec 30.

PMID:
23274926
48.

Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review.

Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C.

Cancer Treat Rev. 2012 Nov;38(7):926-34. doi: 10.1016/j.ctrv.2012.05.002. Epub 2012 Jun 2. Review.

PMID:
22658913
49.

Very high GFR in cancer patients undergoing chemotherapy: prevalence, carboplatin dosing patterns and chemotherapy toxicity.

Roy AC, Jones DN, Slavotinek JP, Kichenadasse G, Karapetis C, Lam E, Bishnoi S, Koczwara B.

Asia Pac J Clin Oncol. 2011 Sep;7(3):281-6. doi: 10.1111/j.1743-7563.2011.01409.x.

PMID:
21884440
50.

Early stage ovarian cancers: angiogenesis inhibition and clear cell cancers.

Kichenadasse G, Sukumaran S, Karapetis C.

Gynecol Oncol. 2011 Nov;123(2):426; author reply 427. doi: 10.1016/j.ygyno.2011.07.036. Epub 2011 Aug 16. No abstract available.

PMID:
21846574

Supplemental Content

Loading ...
Support Center